Predictors of disease severity in SARS-CoV-2 omicron variant XBB sublineages and variants of interest.
COVID-19
Omicron sublineage
Singapore
whole genome sequencing
Journal
Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876
Informations de publication
Date de publication:
11 2023
11 2023
Historique:
revised:
20
09
2023
received:
05
08
2023
accepted:
18
10
2023
medline:
9
11
2023
pubmed:
8
11
2023
entrez:
8
11
2023
Statut:
ppublish
Résumé
The Omicron variant has been reported to present with milder disease compared with Delta, although this may be due to immunity from vaccination and prior exposure. Predictors of severity with recent strains have not been well characterized. We retrospectively examined consecutive cases of moderate-to-severe COVID-19 (defined as requiring supplemental oxygenation, intensive care or mortality) admitted to seven tertiary hospitals across Singapore in April 2023. Whole genome sequencing was performed on each isolate to determine the sublineage, while baseline clinical, laboratory data and outcomes were tabulated. We reviewed 182 patients with moderate-to-severe illness and 466 controls hospitalized at the same time. Advanced age and presence of chronic kidney disease predicted adverse outcome. Previously reported markers such as radiographic evidence of pneumonia, elevated C-reactive protein and serum creatinine levels at presentation also correlated with adverse outcomes. There were no observable differences in outcomes with any specific Omicron XBB sublineage. We did not find any specific Omicron XBB sublineage that was associated with worse outcomes. Larger multinational studies would be important to track the clinical evolution of the virus in its current endemic state.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e29204Informations de copyright
© 2023 Wiley Periodicals LLC.
Références
Ngiam JN, Chhabra S, Goh W, et al. Continued demographic shifts in hospitalised patients with COVID-19 from migrant workers to a vulnerable and more elderly local population at risk of severe disease. Int J Infect Dis. 2023;127:77-84. doi:10.1016/j.ijid.2022.12.007
Ngiam JN, Al-Mubaarak A, Maurer-Stroh S, Tambyah PA. Does the COVID-19 XBB Omicron subvariant signal the beginning of the end of the pandemic? Singapore Med J. 2022. Published online December 1. doi:10.4103/singaporemedj.SMJ-2022-180
Hyams C, Challen R, Marlow R, et al. Severity of Omicron (B.1.1.529) and Delta (B.1.617.2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom. Lancet Reg Health Eur. 2023;25:100556. doi:10.1016/j.lanepe.2022.100556
Sigal A. Milder disease with Omicron: is it the virus or the pre-existing immunity? Nat Rev Immunol. 2022;22(2):69-71. doi:10.1038/s41577-022-00678-4
Nealon J, Cowling BJ. Omicron severity: milder but not mild. The Lancet. 2022;399(10323):412-413. doi:10.1016/S0140-6736(22)00056-3
Ngiam JN, Chew NWS, Tham SM, et al. Utility of conventional clinical risk scores in a low-risk COVID-19 cohort. BMC Infect Dis. 2021;21(1):1094. doi:10.1186/s12879-021-06768-3
Ngiam JN, Liong TS, Chew NWS, et al. Serum creatinine to absolute lymphocyte count ratio effectively risk stratifies patients who require intensive care in hospitalized patients with coronavirus disease 2019. Medicine. 2022;101(38):e30755. doi:10.1097/MD.0000000000030755